NASDAQ:MSON - Misonix Stock Price, Forecast & News

Misonix's stock was trading at $10.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MSON stock has decreased by 11.9% and is now trading at $9.41. View which stocks have been mosted impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Misonix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Misonix.

Misonix is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Misonix.

Misonix, Inc. (NASDAQ:MSON) released its quarterly earnings results on Wednesday, February, 5th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.08. The medical equipment provider earned $19.72 million during the quarter. Misonix had a negative net margin of 14.40% and a negative return on equity of 7.80%. View Misonix's earnings history.

Misonix updated its FY 2020 After-Hours earnings guidance on Wednesday, February, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $46.618 million, compared to the consensus revenue estimate of $73.25 million.

2 equities research analysts have issued twelve-month target prices for Misonix's stock. Their forecasts range from $27.00 to $30.00. On average, they anticipate Misonix's stock price to reach $28.50 in the next twelve months. This suggests a possible upside of 202.9% from the stock's current price. View analysts' price targets for Misonix.

Press coverage about MSON stock has trended negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Misonix earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMisonix.

Some companies that are related to Misonix include Linx (LINX), Kainos Group (KNOS), Photronics (PLAB), Team17 Group (TM17), Oxford Instruments (OXIG), Upwork (UPWK), Onespan (OSPN), Ultra Clean (UCTT), Talend (TLND), Vocera Communications (VCRA), Maxar Technologies (MAXR), Upland Software (UPLD), Axcelis Technologies (ACLS), AudioCodes (AUDC) and Oxford Instruments (OXINF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Misonix investors own include Edap Tms (EDAP), Canopy Growth (CGC), Varian Medical Systems (VAR), Second Sight Medical Products (EYES), Sociedad Quimica y Minera de Chile (SQM), NovaBay Pharmaceuticals (NBY), Aurora Cannabis (ACBFF), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE) and Amicus Therapeutics (FOLD).

Misonix trades on the NASDAQ under the ticker symbol "MSON."

Misonix's stock is owned by many different institutional and retail investors. Top institutional investors include Parkman Healthcare Partners LLC (1.22%), Renaissance Technologies LLC (0.82%), Geode Capital Management LLC (0.81%), State Street Corp (0.86%), Essex Investment Management Co. LLC (0.56%) and Ingalls & Snyder LLC (0.31%). Company insiders that own Misonix stock include Christopher H Wright, Joseph J Brennan, Joseph P Dwyer, Sharon W Klugewicz and Stavros G Vizirgianakis. View institutional ownership trends for Misonix.

MSON stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Martingale Asset Management L P, Acadian Asset Management LLC, Bessemer Group Inc., and Ingalls & Snyder LLC. View insider buying and selling activity for Misonix.

MSON stock was acquired by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, State Street Corp, Geode Capital Management LLC, Bank of Montreal Can, Tiedemann Advisors LLC, DAVENPORT & Co LLC, Bank of America Corp DE, and Charles Schwab Investment Management Inc.. Company insiders that have bought Misonix stock in the last two years include Joseph P Dwyer, Sharon W Klugewicz, and Stavros G Vizirgianakis. View insider buying and selling activity for Misonix.

Shares of MSON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MSON stock can currently be purchased for approximately $9.41.

Misonix has a market capitalization of $163.36 million and generates $38.85 million in revenue each year. Misonix employs 118 workers across the globe. View additional information about Misonix.

The official website for Misonix is http://www.misonix.com/.

Misonix's mailing address is 1938 NEW HIGHWAY, FARMINGDALE NY, 11735. The medical equipment provider can be reached via phone at 631-694-9555.